Generic tamsulosin put to the test: will it match the brand?
NCT ID NCT07698275
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This trial investigates whether a test version of tamsulosin 0.4 mg prolonged-release tablets works the same as the reference product (Omnic Ocas) in healthy male volunteers. Thirty-four men aged 18 to 55 will receive single doses of each tablet under fasted conditions in a crossover design. The study measures how the drug is absorbed and processed by the body to determine bioequivalence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tamsulosin
- What this could lead to
- If the test tablet is shown to be bioequivalent, it could offer a more affordable alternative to the reference product for treating enlarged prostate symptoms.
- What could go wrong
- This is a small, early-stage study in healthy volunteers, not patients. Results may not predict real-world effectiveness or safety in the intended population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOEQUIVALANCE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Axis Clinicals Latina, S.A. de C.V.
Mexico City, Mexico City, 0870, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.